Advertisement

 

 

mTOR Inhibition & Cardiovascular Diseases: Dyslipidemia and Atherosclerosis.

mTOR Inhibition & Cardiovascular Diseases: Dyslipidemia and Atherosclerosis.
Author Information (click to view)

Kurdi A, Martinet W, De Meyer GR,


Kurdi A, Martinet W, De Meyer GR, (click to view)

Kurdi A, Martinet W, De Meyer GR,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Transplantation 2017 02 23() doi 10.1097/TP.0000000000001693
Abstract

Inhibitors of the mechanistic target of rapamycin (mTOR) have unique anti-atherosclerotic effects such as depletion of plaque macrophages, induction of autophagy and activation of cholesterol efflux. However, a common side effect of their use is dyslipidemia, a well-known risk factor for atherosclerosis. Indeed, mTOR inhibitors prevent lipid storage, increase LDL cholesterol levels and activate lipolysis. Although the net effect of mTOR inhibition seems favorable, the use of cholesterol lowering drugs to manage dyslipidemia remains the most recommended strategy.

Submit a Comment

Your email address will not be published. Required fields are marked *

eighteen − thirteen =

[ HIDE/SHOW ]